Hospital Universitari Germans Trias i Pujol -ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2022

  1. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24